Am J Clin Nutr 101 , 218227, (2015)
Phase 1 Trials In a first-in-human, randomized, placebo-controlled, single ascending dose, phase 1 trial in healthy participants, retatrutide demonstrated a favourable safety profile (similar to other incretin-based therapies) and early signs of efficacy with dose-dependent WL [42]
Studies indicate that when patients receive timely feedback on their condition and treatment efficacy, they typically exhibit higher compliance and a more positive outlook on their treatment [216,217,218]
This is not a guaranteed effect, it doesn't work the same way for every patient, and it can't be promised by any program